Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.

Midori ShimadaHiroyuki YamaguchiMinoru FukudaHiromi TomonoNoritaka HondaYosuke DotsuHirokazu TaniguchiHiroshi GyotokuHiroaki SenjuShinnosuke TakemotoTakaya IkedaKatsumi NakatomiYoichi NakamuraSeiji NagashimaTakuya YamazakiHiroshi Mukae

Published in: Cancer chemotherapy and pharmacology (2019)

When this regimen was combined with TRT for LD-SCLC, the MTD was 30 mg/m2 for amrubicin and 60 mg/m2 for cisplatin. In addition, neutropenia and leukopenia were DLT, and doses of 25 mg/m2 for amrubicin and 60 mg/m2 for cisplatin are recommended for this regimen.

Keyphrases

small cell lung cancer
locally advanced
early stage
radiation therapy
spinal cord
clinical trial
squamous cell carcinoma
open label
rectal cancer
brain metastases